Meeting
2013 ASCO Annual Meeting
Extended adjuvant tamoxifen for early breast cancer: A meta-analysis.
Authors
Eitan Amir
Division of Medical Oncology & Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada
Eitan Amir , Mustafa Al-Mubarak , Ariadna Tibau , Arnoud J. Templeton , Alberto Ocana , Bostjan Seruga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 539)
DOI
10.1200/jco.2013.31.15_suppl.539
Abstract #
539
Poster Bd #
1B
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).
First Author: Anne-Vibeke Lænkholm
Poster
2015 ASCO Annual Meeting
Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.
First Author: Anne-Vibeke Lænkholm
First Author: Bent Ejlertsen
Poster
2012 ASCO Annual Meeting
Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.
First Author: Jason Christiansen